PharmAla Files IP Protection For Novel MDXX Molecule: Viability As Autism Spectrum Treatment
Portfolio Pulse from Lara Goldstein
PharmAla Biotech Holdings (OTC:PMBHF) has filed a patent for a Novel Chemical Entity (NCE) PharmAla-1, discovered through computational in-silico modeling. The molecule has undergone a year of preclinical research and shows potential for treating Autism Spectrum Disorder (ASD). The company believes PharmAla-1 will have an improved toxicology profile compared to traditional MDXX compounds. PharmAla's drug development pipeline is set to advance throughout 2023, with the ALA family soon moving into clinical development.
July 31, 2023 | 10:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PharmAla Biotech has filed a patent for a new molecule, PharmAla-1, which shows potential for treating Autism Spectrum Disorder. This could lead to new revenue streams for the company if the molecule proves effective and safe in clinical trials.
The filing of a patent for a new molecule that shows potential for treating Autism Spectrum Disorder could lead to new revenue streams for PharmAla Biotech if the molecule proves effective and safe in clinical trials. This could have a positive impact on the company's stock price in the short term.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100